Abstract
Background: There are over 44 million persons who suffer with Alzheimer’s disease (AD) worldwide, no existence of cure and only symptomatic treatments are available for it. The aim of this study is to evaluate the anti-Alzheimer potential of designed AChEI analogues using computer simulation docking studies. AChEIs are the most potential standards for treatment of AD, because they have proven efficacy. Among all AChEIs donepezil possesses lowest adverse effects, it can treat mildmoderate- severe AD and only once-daily dosing is required. Therefore, donepezil is recognized as a significant prototype for design and development of new drug molecule.
Methods: In this study the Inhibitory potential of the design compounds on acetylcholinesterase enzyme has been evaluated. Docking studies has been performed which further analyzed by in-silico pharmacokinetic evaluation through pharmacopredicta after that Interaction modes with enzyme active sites were determined. Docking studies revealed that there is a strong interaction between the active sites of AChE enzyme and analyzed compounds. Results: As a result 26 compounds have been indicates better inhibitory activity on AChE enzyme and all the screening parameters have also been satisfied by all 26 compounds. From these 26 compounds, six compounds 17, 18, 24, 30, 36 and 56 are found to be the most potent inhibitors of this series by insilico study through INVENTUS v 1.1 software, having highest bio-affinities i.e. - 8.51, - 7.67, - 8.30, - 7.59, - 8.71 and -7.62 kcal/mol respectively, while the standard or reference drug donepezil had binding affinity of - 6.32 kcal/mol. Conclusion: Computer aided drug design approach has been playing an important role in the design and development of novel anti- AD drugs. With the help of structure based drug design some novel analogues of donepezil have been designed and the molecular docking studies with structure based ADME properties prediction studies is performed for prediction of AChE inhibitory activity. The binding mode of proposed compounds with target protein i.e. AChE has been evaluated and the resulting data from docking studies explains that all of the newly designed analogues had significantly high affinity towards target protein compared to donepezil as a reference ligand.Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors (AChEIs), CADD, Structure based drug design, molecular docking.
Graphical Abstract
[1]
Daina, A.; Blatter, M.C.; Baillie Gerritsen, V.; Palagi, P.M.; Marek, D.; Xenarios, I. Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public. J. Chem. Educ., 2017, 94(3), 335-344.
[http://dx.doi.org/10.1021/acs.jchemed.6b00596]
[http://dx.doi.org/10.1021/acs.jchemed.6b00596]
[2]
Medical chemistry project. (Accessed from: http://medicinalchemistryproject.info/-images/processgraphic.jpg
[3]
We speak science. (Accessed from: https://wespeakscience.com/wpcontent/uploads-/2017/07/Drug-Development-750x400.jpg
[4]
Xiang, M.; Cao, Y.; Fan, W.; Chen, L.; Mo, Y. Computer-aided drug design: Lead discovery and optimization. Comb. Chem. High Throughput Screen., 2012, 15(4), 328-337.
[http://dx.doi.org/10.2174/138620712799361825] [PMID: 22221065]
[http://dx.doi.org/10.2174/138620712799361825] [PMID: 22221065]
[5]
Ghanemi, A. Alzheimer’s disease therapies: Selected advances and future perspectives. Alexandria Journal of Medicine., 2015, 51(1), 1-3.
[http://dx.doi.org/10.1016/j.ajme.2014.09.006]
[http://dx.doi.org/10.1016/j.ajme.2014.09.006]
[6]
Gustavsson, A.; Green, C.; Jones, R.W.; Förstl, H.; Simsek, D.; de Reydet de Vulpillieres, F.; Luthman, S.; Adlard, N.; Bhattacharyya, S.; Wimo, A. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease. Alzheimers Dement., 2017, 13(3), 312-321.
[http://dx.doi.org/10.1016/j.jalz.2016.12.005] [PMID: 28063281]
[http://dx.doi.org/10.1016/j.jalz.2016.12.005] [PMID: 28063281]
[7]
Zeb, M.W.; Riaz, A.; Szigeti, K. Donepezil: A review of pharmacological characteristics and role in the management of alzheimer disease. Clinical Medicine Insights: Geriatrics., 2017, 10, 1-14.
[8]
Gouri, K.S.; Dani, K.J.; Chowdary, K.P. Evaluation of drug treatment options for Alzheimer’s disease - a review of earlier studies. World J. Pharm. Pharm. Sci., 2017, 6(4), 177-182.
[http://dx.doi.org/10.20959/wjpps20174-8726]
[http://dx.doi.org/10.20959/wjpps20174-8726]
[9]
Sugimoto, H. The new approach in development of anti-Alzheimer’s disease drugs via the cholinergic hypothesis. Chem. Biol. Interact., 2008, 175(1-3), 204-208.
[http://dx.doi.org/10.1016/j.cbi.2008.05.031] [PMID: 18577377]
[http://dx.doi.org/10.1016/j.cbi.2008.05.031] [PMID: 18577377]
[10]
Christensen, D.D. Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer’s disease. Postgrad. Med., 2012, 124(6), 110-116.
[http://dx.doi.org/10.3810/pgm.2012.11.2589] [PMID: 23322144]
[http://dx.doi.org/10.3810/pgm.2012.11.2589] [PMID: 23322144]
[11]
Zeng, H.; Wu, X. Alzheimer’s disease drug development based on Computer-Aided Drug Design. Eur. J. Med. Chem., 2016, 121, 851-863.
[http://dx.doi.org/10.1016/j.ejmech.2015.08.039] [PMID: 26415837]
[http://dx.doi.org/10.1016/j.ejmech.2015.08.039] [PMID: 26415837]
[13]
Cheung, J.; Rudolph, M.J.; Burshteyn, F.; Cassidy, M.S.; Gary, E.N.; Love, J.; Franklin, M.C.; Height, J.J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem., 2012, 55(22), 10282-10286.
[http://dx.doi.org/10.1021/jm300871x] [PMID: 23035744]
[http://dx.doi.org/10.1021/jm300871x] [PMID: 23035744]
[14]
Sağlık, B.N.; Ilgın, S.; Özkay, Y. Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. Eur. J. Med. Chem., 2016, 124, 1026-1040.
[http://dx.doi.org/10.1016/j.ejmech.2016.10.042] [PMID: 27783974]
[http://dx.doi.org/10.1016/j.ejmech.2016.10.042] [PMID: 27783974]
[15]
Sugimoto, H.; Ogura, H.; Arai, Y.; Limura, Y.; Yamanishi, Y. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol., 2002, 89(1), 7-20.
[http://dx.doi.org/10.1254/jjp.89.7] [PMID: 12083745]
[http://dx.doi.org/10.1254/jjp.89.7] [PMID: 12083745]
[20]
Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today. Technol., 2004, 1(4), 337-341.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[21]
Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1(9), 727-730.
[http://dx.doi.org/10.1038/nrd892] [PMID: 12209152]
[http://dx.doi.org/10.1038/nrd892] [PMID: 12209152]
[22]
Pajouhesh, H.; Lenz, G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx, 2005, 2(4), 541-553.
[http://dx.doi.org/10.1602/neurorx.2.4.541] [PMID: 16489364]
[http://dx.doi.org/10.1602/neurorx.2.4.541] [PMID: 16489364]
Article Metrics
30
2